These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 31871266

  • 1. Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.
    Zheng Z, Okada R, Kobayashi H, Nagaya T, Wei J, Zhou Q, Lee F, Bera TK, Gao Y, Kuhlman W, Tai CH, Pastan I.
    Mol Cancer Ther; 2020 Mar; 19(3):812-821. PubMed ID: 31871266
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
    Hollevoet K, Mason-Osann E, Müller F, Pastan I.
    PLoS One; 2015 Mar; 10(3):e0122462. PubMed ID: 25803818
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
    Cerise A, Bera TK, Liu X, Wei J, Pastan I.
    Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
    [Abstract] [Full Text] [Related]

  • 8. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics.
    Nguyen MQ, Kim DH, Shim HJ, Ta HKK, Vu TL, Nguyen TKO, Lim JC, Choe H.
    Mol Cells; 2023 Dec 31; 46(12):764-777. PubMed ID: 38052492
    [Abstract] [Full Text] [Related]

  • 9. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
    Ali-Rahmani F, FitzGerald DJ, Martin S, Patel P, Prunotto M, Ormanoglu P, Thomas C, Pastan I.
    Cancer Res; 2016 Mar 15; 76(6):1560-8. PubMed ID: 26719540
    [Abstract] [Full Text] [Related]

  • 10. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
    Kolyvas E, Rudloff M, Poruchynsky M, Landsman R, Hollevoet K, Venzon D, Alewine C.
    Oncotarget; 2017 Feb 07; 8(6):9189-9199. PubMed ID: 27999204
    [Abstract] [Full Text] [Related]

  • 11. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 07; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
    Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J, Hassan R, Pastan I.
    Oncotarget; 2016 May 24; 7(21):29916-26. PubMed ID: 27167198
    [Abstract] [Full Text] [Related]

  • 15. Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.
    Liu X, Müller F, Wayne AS, Pastan I.
    Mol Cancer Ther; 2016 May 24; 15(5):1053-62. PubMed ID: 26939705
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine.
    Liu XF, Wei J, Zhou Q, Molitoris BA, Sandoval R, Kobayashi H, Okada R, Nagaya T, Karim B, Butcher D, Pastan I.
    Proc Natl Acad Sci U S A; 2020 Mar 17; 117(11):6086-6091. PubMed ID: 32123080
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
    Simon M, Stefan N, Borsig L, Plückthun A, Zangemeister-Wittke U.
    Mol Cancer Ther; 2014 Feb 17; 13(2):375-85. PubMed ID: 24184633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.